Dr. O'Shaughnessy on Differentiating Between CDK 4/6 Inhibitors | OncLive

Dr. O'Shaughnessy on Differentiating Between CDK 4/6 Inhibitors

March 11, 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

Individual patients will experience different side effects with both palbociclib and ribociclib, O’Shaughnessy explains, so physicians can choose when to switch a patient from one to another.

Abemaciclib data is still to be reported, but O’Shaughnessy hopes the agent will be on the market soon. At this time, O’Shaughnessy says, it looks like abemaciclib may provide benefit for patients with heavily pre-treated breast cancer.

She additionally notes that she is impressed with abemaciclib’s ability to penetrate the blood brain barrier and control brain metastases. Overall, O’Shaughnessy says this is an exciting time in breast cancer.

<<<

View more from the 2017 Miami Breast Cancer Conference


x